A Bad Sign: Dermatomyositis with Interstitial Lung Disease

Am J Med. 2019 Feb;132(2):182-186. doi: 10.1016/j.amjmed.2018.09.013. Epub 2018 Sep 19.

Authors

Siriwan Palawisuth¹, Kornphaka Kantikosum², Mattana Patiyasikunt¹, Thitiwat Sriprasart³, Pravit Asawanonda¹, Pawinee Rerknimitr¹

Affiliations

¹ Division of Dermatology, Department of Medicine, Faculty of Medicine, The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand.
² Division of Dermatology, Department of Medicine, Faculty of Medicine, The Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand. Electronic address: Ploykornphaka@gmail.com.
³ Division of Pulmonary and Critical Care, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.

PMID: 30243507
DOI: 10.1016/j.amjmed.2018.09.013

No abstract available

Publication types

Case Reports

MeSH terms

Anti-Inflammatory Agents / administration & dosage
Anti-Inflammatory Agents / therapeutic use
Azathioprine / administration & dosage
Azathioprine / therapeutic use
Dermatomyositis / complications
Dermatomyositis / diagnosis*
Dexamethasone / administration & dosage
Dexamethasone / therapeutic use
Fatal Outcome
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / therapeutic use
Lung Diseases, Interstitial / complications
Lung Diseases, Interstitial / diagnosis*
Male
Middle Aged

Substances

Anti-Inflammatory Agents
Immunosuppressive Agents
Dexamethasone
Azathioprine